 Liron Caplan
Concepts (337)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Spondylitis, Ankylosing | 12 | 2024 | 43 | 6.230 |
Why?
| | Arthritis, Rheumatoid | 51 | 2019 | 1002 | 5.470 |
Why?
| | Rheumatology | 15 | 2023 | 89 | 4.670 |
Why?
| | Spondylarthritis | 10 | 2024 | 36 | 4.410 |
Why?
| | Antirheumatic Agents | 27 | 2019 | 255 | 3.920 |
Why?
| | Osteoporosis | 10 | 2023 | 227 | 2.070 |
Why?
| | Severity of Illness Index | 26 | 2023 | 2578 | 1.710 |
Why?
| | Glucocorticoids | 10 | 2023 | 552 | 1.690 |
Why?
| | Health Literacy | 5 | 2019 | 166 | 1.630 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 5 | 2023 | 301 | 1.610 |
Why?
| | Gastrointestinal Diseases | 3 | 2018 | 184 | 1.590 |
Why?
| | Methotrexate | 11 | 2018 | 228 | 1.230 |
Why?
| | Arthritis | 2 | 2019 | 111 | 1.170 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 3 | 2015 | 242 | 1.120 |
Why?
| | Registries | 20 | 2018 | 1770 | 1.100 |
Why?
| | Decision Support Systems, Management | 2 | 2015 | 6 | 0.980 |
Why?
| | Methylenetetrahydrofolate Reductase (NADPH2) | 2 | 2014 | 34 | 0.890 |
Why?
| | Sacroiliitis | 1 | 2022 | 3 | 0.860 |
Why?
| | Cardiovascular Diseases | 9 | 2023 | 1724 | 0.830 |
Why?
| | Fractures, Bone | 3 | 2023 | 372 | 0.790 |
Why?
| | Bone Density Conservation Agents | 4 | 2014 | 62 | 0.780 |
Why?
| | Humans | 98 | 2024 | 115587 | 0.770 |
Why?
| | Body Mass Index | 10 | 2018 | 1971 | 0.750 |
Why?
| | Health Knowledge, Attitudes, Practice | 4 | 2015 | 1198 | 0.740 |
Why?
| | Veterans | 13 | 2019 | 1233 | 0.730 |
Why?
| | Outpatient Clinics, Hospital | 2 | 2011 | 79 | 0.720 |
Why?
| | Arthritis, Psoriatic | 2 | 2023 | 16 | 0.720 |
Why?
| | Transportation | 1 | 2019 | 44 | 0.680 |
Why?
| | Rheumatic Diseases | 2 | 2018 | 49 | 0.670 |
Why?
| | Inflammatory Bowel Diseases | 3 | 2018 | 289 | 0.660 |
Why?
| | Drug Packaging | 1 | 2019 | 43 | 0.660 |
Why?
| | Aged | 44 | 2019 | 19251 | 0.660 |
Why?
| | Gastrointestinal Tract | 2 | 2018 | 168 | 0.650 |
Why?
| | United States | 33 | 2023 | 12295 | 0.640 |
Why?
| | Middle Aged | 48 | 2019 | 26999 | 0.630 |
Why?
| | Conflict of Interest | 1 | 2020 | 120 | 0.630 |
Why?
| | Visual Analog Scale | 2 | 2019 | 30 | 0.620 |
Why?
| | Antibodies, Antineutrophil Cytoplasmic | 1 | 2018 | 33 | 0.600 |
Why?
| | Joints | 3 | 2013 | 84 | 0.600 |
Why?
| | Pharmaceutical Preparations | 1 | 2019 | 169 | 0.590 |
Why?
| | Vasculitis | 1 | 2018 | 71 | 0.590 |
Why?
| | Disability Evaluation | 2 | 2018 | 271 | 0.580 |
Why?
| | Medication Therapy Management | 1 | 2018 | 67 | 0.570 |
Why?
| | Diphosphonates | 3 | 2014 | 51 | 0.560 |
Why?
| | Male | 57 | 2022 | 55949 | 0.550 |
Why?
| | Cross-Sectional Studies | 16 | 2019 | 4435 | 0.550 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2018 | 126 | 0.550 |
Why?
| | Tumor Necrosis Factor-alpha | 8 | 2022 | 1137 | 0.540 |
Why?
| | Patient Satisfaction | 2 | 2019 | 585 | 0.510 |
Why?
| | Surveys and Questionnaires | 7 | 2016 | 4665 | 0.510 |
Why?
| | Health Care Costs | 1 | 2019 | 384 | 0.510 |
Why?
| | Weight Loss | 5 | 2018 | 633 | 0.500 |
Why?
| | Patient Education as Topic | 4 | 2015 | 686 | 0.500 |
Why?
| | Liver Diseases | 1 | 2018 | 263 | 0.500 |
Why?
| | Attitude of Health Personnel | 2 | 2013 | 990 | 0.500 |
Why?
| | Practice Patterns, Physicians' | 3 | 2015 | 1180 | 0.500 |
Why?
| | Diabetes Mellitus, Type 2 | 4 | 2022 | 2098 | 0.500 |
Why?
| | Female | 50 | 2019 | 59913 | 0.470 |
Why?
| | gamma-Glutamyl Hydrolase | 1 | 2014 | 2 | 0.470 |
Why?
| | Peptide Synthases | 1 | 2014 | 3 | 0.470 |
Why?
| | Veterans Health | 5 | 2017 | 165 | 0.460 |
Why?
| | Risk Factors | 24 | 2023 | 8697 | 0.460 |
Why?
| | Arthroplasty, Replacement, Hip | 1 | 2015 | 109 | 0.460 |
Why?
| | Patient Reported Outcome Measures | 1 | 2016 | 250 | 0.460 |
Why?
| | Lipids | 2 | 2014 | 588 | 0.450 |
Why?
| | Protein Kinase Inhibitors | 1 | 2019 | 790 | 0.450 |
Why?
| | Proteins | 1 | 2019 | 920 | 0.450 |
Why?
| | Biomedical Research | 1 | 2019 | 588 | 0.450 |
Why?
| | Health Status | 3 | 2018 | 728 | 0.440 |
Why?
| | Societies, Medical | 5 | 2019 | 684 | 0.440 |
Why?
| | Spondylarthropathies | 3 | 2019 | 6 | 0.440 |
Why?
| | Activities of Daily Living | 1 | 2016 | 352 | 0.440 |
Why?
| | Folic Acid | 1 | 2014 | 159 | 0.420 |
Why?
| | Symptom Assessment | 1 | 2013 | 121 | 0.420 |
Why?
| | Obesity | 5 | 2018 | 2517 | 0.420 |
Why?
| | Electronic Health Records | 3 | 2015 | 805 | 0.420 |
Why?
| | Pharmacists | 1 | 2015 | 237 | 0.420 |
Why?
| | Consumer Behavior | 1 | 2013 | 66 | 0.420 |
Why?
| | Physical Therapy Modalities | 1 | 2015 | 269 | 0.420 |
Why?
| | Health Personnel | 3 | 2014 | 581 | 0.410 |
Why?
| | Hospitals, Public | 1 | 2011 | 23 | 0.390 |
Why?
| | Prednisone | 5 | 2018 | 232 | 0.380 |
Why?
| | Pain | 2 | 2022 | 712 | 0.380 |
Why?
| | Telemedicine | 1 | 2019 | 667 | 0.360 |
Why?
| | Anti-Inflammatory Agents | 4 | 2018 | 448 | 0.350 |
Why?
| | Randomized Controlled Trials as Topic | 4 | 2022 | 1216 | 0.350 |
Why?
| | Autoantibodies | 5 | 2019 | 1360 | 0.350 |
Why?
| | Musculoskeletal Diseases | 1 | 2010 | 55 | 0.330 |
Why?
| | Physician-Patient Relations | 2 | 2011 | 465 | 0.330 |
Why?
| | Cerebrovascular Disorders | 3 | 1997 | 82 | 0.330 |
Why?
| | Efficiency, Organizational | 1 | 2010 | 126 | 0.330 |
Why?
| | Workflow | 1 | 2010 | 136 | 0.330 |
Why?
| | Adalimumab | 4 | 2020 | 44 | 0.320 |
Why?
| | Linear Models | 5 | 2019 | 776 | 0.320 |
Why?
| | Practice Guidelines as Topic | 5 | 2018 | 1405 | 0.310 |
Why?
| | Publications | 1 | 2008 | 37 | 0.310 |
Why?
| | United States Department of Veterans Affairs | 8 | 2016 | 557 | 0.300 |
Why?
| | Ethics, Medical | 1 | 2008 | 70 | 0.300 |
Why?
| | Patient Compliance | 1 | 2012 | 524 | 0.300 |
Why?
| | Adult | 20 | 2023 | 30718 | 0.300 |
Why?
| | Aged, 80 and over | 11 | 2019 | 6417 | 0.290 |
Why?
| | Etanercept | 3 | 2016 | 51 | 0.280 |
Why?
| | Diabetes Mellitus | 1 | 2015 | 906 | 0.280 |
Why?
| | Ambulatory Care | 1 | 2010 | 478 | 0.280 |
Why?
| | Infliximab | 3 | 2016 | 94 | 0.270 |
Why?
| | Radiography | 3 | 2019 | 826 | 0.270 |
Why?
| | Treatment Outcome | 13 | 2019 | 9159 | 0.270 |
Why?
| | Time Factors | 11 | 2018 | 6165 | 0.270 |
Why?
| | Drug Utilization | 3 | 2018 | 167 | 0.260 |
Why?
| | Longitudinal Studies | 9 | 2019 | 2416 | 0.250 |
Why?
| | Professional Practice | 1 | 2005 | 63 | 0.250 |
Why?
| | Quality of Life | 1 | 2016 | 2385 | 0.250 |
Why?
| | Peptides, Cyclic | 4 | 2016 | 262 | 0.240 |
Why?
| | Reproducibility of Results | 5 | 2016 | 2800 | 0.230 |
Why?
| | Cohort Studies | 11 | 2015 | 4944 | 0.230 |
Why?
| | Polymorphism, Single Nucleotide | 4 | 2019 | 1918 | 0.230 |
Why?
| | Retrospective Studies | 11 | 2022 | 12608 | 0.220 |
Why?
| | Predictive Value of Tests | 5 | 2018 | 1805 | 0.220 |
Why?
| | Rheumatoid Factor | 3 | 2016 | 157 | 0.220 |
Why?
| | Dose-Response Relationship, Drug | 5 | 2014 | 1870 | 0.220 |
Why?
| | Adrenal Cortex Hormones | 1 | 2007 | 509 | 0.220 |
Why?
| | Bone Density | 4 | 2023 | 432 | 0.220 |
Why?
| | Evidence-Based Medicine | 2 | 2018 | 684 | 0.210 |
Why?
| | Myocardial Infarction | 3 | 2018 | 931 | 0.210 |
Why?
| | Inflammation | 4 | 2018 | 2499 | 0.210 |
Why?
| | Biomarkers | 5 | 2022 | 3466 | 0.210 |
Why?
| | Prognosis | 6 | 2016 | 3339 | 0.200 |
Why?
| | Lymphocytes | 1 | 2022 | 344 | 0.190 |
Why?
| | Proportional Hazards Models | 6 | 2016 | 1087 | 0.190 |
Why?
| | Neutrophils | 2 | 2024 | 1172 | 0.180 |
Why?
| | Multivariate Analysis | 8 | 2018 | 1440 | 0.180 |
Why?
| | Risk Assessment | 7 | 2018 | 2987 | 0.180 |
Why?
| | C-Reactive Protein | 3 | 2017 | 364 | 0.180 |
Why?
| | Granuloma, Foreign-Body | 1 | 2020 | 10 | 0.170 |
Why?
| | Tattooing | 1 | 2020 | 11 | 0.170 |
Why?
| | Comorbidity | 6 | 2018 | 1473 | 0.170 |
Why?
| | Regression Analysis | 3 | 2011 | 959 | 0.170 |
Why?
| | Genotype | 3 | 2014 | 1786 | 0.170 |
Why?
| | Blood Platelets | 1 | 2022 | 350 | 0.170 |
Why?
| | Malondialdehyde | 1 | 2019 | 26 | 0.170 |
Why?
| | Acetaldehyde | 1 | 2019 | 20 | 0.170 |
Why?
| | Blood Glucose | 4 | 2022 | 1824 | 0.170 |
Why?
| | HLA-B27 Antigen | 1 | 2019 | 11 | 0.170 |
Why?
| | Macular Edema | 1 | 2020 | 35 | 0.170 |
Why?
| | Drug Stability | 1 | 2019 | 152 | 0.170 |
Why?
| | Drug Compounding | 1 | 2019 | 89 | 0.170 |
Why?
| | Deprescriptions | 1 | 2019 | 27 | 0.160 |
Why?
| | Protein Stability | 1 | 2019 | 162 | 0.160 |
Why?
| | Biosimilar Pharmaceuticals | 1 | 2019 | 25 | 0.160 |
Why?
| | Uveitis | 1 | 2020 | 115 | 0.160 |
Why?
| | Clinical Trials as Topic | 2 | 2022 | 941 | 0.160 |
Why?
| | Metformin | 1 | 2022 | 278 | 0.160 |
Why?
| | Intraepithelial Lymphocytes | 1 | 2018 | 12 | 0.160 |
Why?
| | Hydroxychloroquine | 2 | 2018 | 55 | 0.160 |
Why?
| | Pyrroles | 1 | 2019 | 185 | 0.160 |
Why?
| | Vertebrobasilar Insufficiency | 1 | 1998 | 7 | 0.150 |
Why?
| | Piperidines | 1 | 2019 | 163 | 0.150 |
Why?
| | Cerebral Infarction | 1 | 1998 | 39 | 0.150 |
Why?
| | Mesencephalon | 1 | 1998 | 57 | 0.150 |
Why?
| | Stress, Mechanical | 1 | 2019 | 440 | 0.150 |
Why?
| | Obesity, Abdominal | 1 | 2017 | 38 | 0.150 |
Why?
| | Medication Adherence | 2 | 2012 | 538 | 0.150 |
Why?
| | Inflammation Mediators | 2 | 2017 | 479 | 0.140 |
Why?
| | Remission Induction | 3 | 2012 | 240 | 0.140 |
Why?
| | Temperature | 1 | 2019 | 587 | 0.140 |
Why?
| | Absorptiometry, Photon | 3 | 2017 | 221 | 0.140 |
Why?
| | Genetic Predisposition to Disease | 3 | 2019 | 2125 | 0.140 |
Why?
| | Thrombolytic Therapy | 1 | 1997 | 118 | 0.140 |
Why?
| | Biological Products | 1 | 2019 | 172 | 0.140 |
Why?
| | Pyrimidines | 1 | 2019 | 376 | 0.140 |
Why?
| | Drug Administration Schedule | 2 | 2010 | 724 | 0.140 |
Why?
| | Research Design | 1 | 2022 | 946 | 0.130 |
Why?
| | Sodium Chloride | 1 | 2016 | 136 | 0.130 |
Why?
| | Tissue Plasminogen Activator | 1 | 1997 | 228 | 0.130 |
Why?
| | Patient Selection | 3 | 2022 | 654 | 0.120 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2019 | 667 | 0.120 |
Why?
| | DNA Methylation | 1 | 2019 | 498 | 0.120 |
Why?
| | Genes, rel | 1 | 2014 | 4 | 0.120 |
Why?
| | Magnetic Resonance Imaging | 3 | 2022 | 3069 | 0.120 |
Why?
| | Lipoproteins, HDL | 1 | 2014 | 76 | 0.120 |
Why?
| | Hand | 1 | 2015 | 134 | 0.110 |
Why?
| | Disease Management | 1 | 2018 | 563 | 0.110 |
Why?
| | Lung Diseases, Interstitial | 1 | 2019 | 520 | 0.110 |
Why?
| | Incidence | 7 | 2018 | 2335 | 0.110 |
Why?
| | Lipoproteins, LDL | 1 | 2014 | 129 | 0.110 |
Why?
| | Diagnosis, Differential | 1 | 2018 | 1357 | 0.110 |
Why?
| | Vascular Calcification | 1 | 2015 | 107 | 0.110 |
Why?
| | Immunosuppressive Agents | 3 | 2009 | 666 | 0.110 |
Why?
| | Femoral Fractures | 1 | 2014 | 67 | 0.110 |
Why?
| | Adiposity | 1 | 2017 | 468 | 0.110 |
Why?
| | Nanoparticles | 1 | 2016 | 316 | 0.110 |
Why?
| | Spinal Fractures | 1 | 2014 | 78 | 0.100 |
Why?
| | Immunoglobulin G | 1 | 2016 | 781 | 0.100 |
Why?
| | Dyslipidemias | 1 | 2014 | 154 | 0.100 |
Why?
| | Chronic Disease | 2 | 2018 | 1598 | 0.100 |
Why?
| | North America | 1 | 2013 | 261 | 0.100 |
Why?
| | Health Services Research | 1 | 2015 | 377 | 0.100 |
Why?
| | Autoimmunity | 1 | 2018 | 822 | 0.100 |
Why?
| | Triglycerides | 1 | 2014 | 473 | 0.100 |
Why?
| | Lung Diseases | 1 | 2018 | 710 | 0.100 |
Why?
| | Gastrointestinal Microbiome | 1 | 2018 | 503 | 0.100 |
Why?
| | Insurance, Pharmaceutical Services | 1 | 2011 | 23 | 0.100 |
Why?
| | Coronary Artery Disease | 1 | 2018 | 607 | 0.100 |
Why?
| | Antibodies, Monoclonal | 2 | 2016 | 1265 | 0.100 |
Why?
| | Young Adult | 3 | 2019 | 10470 | 0.100 |
Why?
| | Polymorphism, Genetic | 2 | 2011 | 621 | 0.100 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2011 | 81 | 0.090 |
Why?
| | Memory Disorders | 1 | 2012 | 155 | 0.090 |
Why?
| | Workload | 1 | 2012 | 133 | 0.090 |
Why?
| | Glutathione Transferase | 1 | 2010 | 95 | 0.090 |
Why?
| | Sex Factors | 4 | 2017 | 1736 | 0.090 |
Why?
| | Hypertension | 1 | 2018 | 1064 | 0.090 |
Why?
| | Follow-Up Studies | 4 | 2015 | 4440 | 0.090 |
Why?
| | Carcinoma, Basal Cell | 1 | 2011 | 68 | 0.090 |
Why?
| | Health Care Surveys | 1 | 2012 | 538 | 0.090 |
Why?
| | Hospitalization | 2 | 2011 | 1765 | 0.090 |
Why?
| | HLA-DR Antigens | 1 | 2010 | 221 | 0.090 |
Why?
| | Pilot Projects | 1 | 2014 | 1377 | 0.080 |
Why?
| | Disease Progression | 4 | 2019 | 2418 | 0.080 |
Why?
| | Health Surveys | 2 | 2012 | 446 | 0.080 |
Why?
| | Interviews as Topic | 1 | 2012 | 596 | 0.080 |
Why?
| | Hip Fractures | 1 | 2010 | 75 | 0.080 |
Why?
| | Prospective Studies | 4 | 2013 | 6264 | 0.080 |
Why?
| | Neoplasms | 3 | 2017 | 2118 | 0.080 |
Why?
| | Cytokines | 1 | 2016 | 1853 | 0.080 |
Why?
| | Vitamin D Deficiency | 1 | 2010 | 159 | 0.080 |
Why?
| | Epitopes | 1 | 2010 | 438 | 0.080 |
Why?
| | Self Care | 1 | 2011 | 354 | 0.080 |
Why?
| | Immunocompromised Host | 2 | 2011 | 197 | 0.080 |
Why?
| | Databases, Bibliographic | 1 | 2008 | 29 | 0.080 |
Why?
| | Beneficence | 1 | 2008 | 18 | 0.080 |
Why?
| | Sensitivity and Specificity | 1 | 2013 | 1718 | 0.080 |
Why?
| | Awards and Prizes | 1 | 1989 | 56 | 0.080 |
Why?
| | Drug Prescriptions | 1 | 2010 | 241 | 0.080 |
Why?
| | Social Justice | 1 | 2008 | 66 | 0.070 |
Why?
| | Administration, Oral | 1 | 2010 | 734 | 0.070 |
Why?
| | Urban Population | 1 | 2010 | 405 | 0.070 |
Why?
| | Algorithms | 1 | 1994 | 1490 | 0.070 |
Why?
| | Research Personnel | 1 | 1989 | 153 | 0.070 |
Why?
| | Qualitative Research | 1 | 2012 | 971 | 0.070 |
Why?
| | Self Administration | 1 | 2007 | 124 | 0.070 |
Why?
| | Infusions, Intravenous | 2 | 2016 | 374 | 0.070 |
Why?
| | Quality of Health Care | 1 | 2011 | 576 | 0.070 |
Why?
| | Depressive Disorder | 1 | 2009 | 336 | 0.070 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2011 | 577 | 0.070 |
Why?
| | Age Factors | 4 | 2015 | 2907 | 0.060 |
Why?
| | Military Personnel | 1 | 2013 | 525 | 0.060 |
Why?
| | Respiratory Tract Diseases | 2 | 2017 | 142 | 0.060 |
Why?
| | Herpes Zoster | 1 | 2009 | 333 | 0.060 |
Why?
| | Disabled Persons | 1 | 2007 | 135 | 0.060 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2013 | 758 | 0.060 |
Why?
| | Cause of Death | 2 | 2017 | 368 | 0.060 |
Why?
| | Databases, Factual | 3 | 2014 | 1138 | 0.060 |
Why?
| | CARD Signaling Adaptor Proteins | 1 | 2024 | 17 | 0.060 |
Why?
| | Skin Neoplasms | 1 | 2011 | 761 | 0.060 |
Why?
| | Th17 Cells | 1 | 2024 | 59 | 0.060 |
Why?
| | Coculture Techniques | 1 | 2024 | 202 | 0.060 |
Why?
| | Interleukin-17 | 1 | 2024 | 106 | 0.050 |
Why?
| | Adolescent | 3 | 2019 | 17889 | 0.050 |
Why?
| | Survival Analysis | 2 | 2018 | 1219 | 0.050 |
Why?
| | Autoantigens | 2 | 2019 | 398 | 0.050 |
Why?
| | Isoxazoles | 2 | 2016 | 56 | 0.050 |
Why?
| | Case-Control Studies | 2 | 2019 | 3022 | 0.050 |
Why?
| | Prevalence | 1 | 2007 | 2264 | 0.050 |
Why?
| | Pneumonia | 1 | 2006 | 576 | 0.040 |
Why?
| | Foreign-Body Reaction | 1 | 2020 | 23 | 0.040 |
Why?
| | Phospholipase D | 1 | 2019 | 7 | 0.040 |
Why?
| | Steroids | 1 | 2020 | 147 | 0.040 |
Why?
| | Child | 3 | 2023 | 18488 | 0.040 |
Why?
| | Machine Learning | 1 | 2022 | 321 | 0.040 |
Why?
| | Sulfasalazine | 1 | 2018 | 21 | 0.040 |
Why?
| | Intracranial Embolism and Thrombosis | 1 | 1998 | 6 | 0.040 |
Why?
| | New England | 1 | 1998 | 27 | 0.040 |
Why?
| | Vulnerable Populations | 1 | 2019 | 138 | 0.040 |
Why?
| | Coronary Thrombosis | 1 | 1998 | 25 | 0.040 |
Why?
| | Microtubule-Associated Proteins | 1 | 2019 | 174 | 0.040 |
Why?
| | Molecular Chaperones | 1 | 2019 | 157 | 0.040 |
Why?
| | Antibody Formation | 1 | 2019 | 273 | 0.040 |
Why?
| | Blood Sedimentation | 1 | 2017 | 34 | 0.040 |
Why?
| | Visual Acuity | 1 | 2020 | 273 | 0.040 |
Why?
| | Infusions, Intra-Arterial | 1 | 1997 | 45 | 0.040 |
Why?
| | Mitochondrial Proteins | 1 | 2019 | 219 | 0.040 |
Why?
| | Rheumatic Nodule | 1 | 2016 | 3 | 0.040 |
Why?
| | Osteoarthritis | 1 | 2019 | 173 | 0.040 |
Why?
| | RNA, Long Noncoding | 1 | 2019 | 157 | 0.040 |
Why?
| | Nutrition Surveys | 1 | 2017 | 225 | 0.030 |
Why?
| | Adsorption | 1 | 2016 | 125 | 0.030 |
Why?
| | Consensus | 1 | 2018 | 532 | 0.030 |
Why?
| | Drug Substitution | 1 | 2016 | 46 | 0.030 |
Why?
| | Administration, Intravenous | 1 | 2016 | 126 | 0.030 |
Why?
| | Protein Aggregates | 1 | 2016 | 66 | 0.030 |
Why?
| | Cerebrovascular Circulation | 1 | 1998 | 202 | 0.030 |
Why?
| | Thinness | 1 | 2016 | 87 | 0.030 |
Why?
| | Biopsy | 1 | 2020 | 1056 | 0.030 |
Why?
| | Mortality | 1 | 2018 | 290 | 0.030 |
Why?
| | Observational Studies as Topic | 1 | 2016 | 89 | 0.030 |
Why?
| | Particle Size | 1 | 2016 | 319 | 0.030 |
Why?
| | Lymphoma | 1 | 2016 | 178 | 0.030 |
Why?
| | Chemokines | 1 | 2016 | 214 | 0.030 |
Why?
| | Epigenesis, Genetic | 1 | 2019 | 526 | 0.030 |
Why?
| | Apolipoproteins E | 1 | 2015 | 81 | 0.030 |
Why?
| | Hypoglycemic Agents | 1 | 2022 | 1008 | 0.030 |
Why?
| | Leukemia | 1 | 2016 | 209 | 0.030 |
Why?
| | Interleukin-4 | 1 | 2015 | 209 | 0.030 |
Why?
| | Cardiac Catheterization | 1 | 2018 | 536 | 0.030 |
Why?
| | Antigen-Antibody Complex | 1 | 2014 | 88 | 0.030 |
Why?
| | Hospitals, Veterans | 1 | 2015 | 245 | 0.030 |
Why?
| | United States Food and Drug Administration | 1 | 2014 | 173 | 0.030 |
Why?
| | Causality | 1 | 2014 | 106 | 0.030 |
Why?
| | Life Style | 1 | 2016 | 429 | 0.030 |
Why?
| | Genome-Wide Association Study | 1 | 2019 | 1217 | 0.030 |
Why?
| | Body Weight | 1 | 2016 | 867 | 0.030 |
Why?
| | Blood Pressure | 1 | 2018 | 1537 | 0.020 |
Why?
| | Survival Rate | 1 | 2015 | 1650 | 0.020 |
Why?
| | Data Mining | 1 | 2011 | 100 | 0.020 |
Why?
| | Propensity Score | 1 | 2011 | 225 | 0.020 |
Why?
| | HLA-DRB1 Chains | 1 | 2010 | 98 | 0.020 |
Why?
| | Logistic Models | 1 | 2015 | 1856 | 0.020 |
Why?
| | Pancreatic Neoplasms | 1 | 2016 | 722 | 0.020 |
Why?
| | Prostatic Neoplasms | 1 | 2016 | 927 | 0.020 |
Why?
| | Smoking | 1 | 2016 | 1457 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 795 | 0.020 |
Why?
| | Risk | 1 | 2011 | 819 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 1997 | 2392 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2010 | 1000 | 0.020 |
Why?
| | Mice | 1 | 2024 | 15052 | 0.020 |
Why?
| | American Heart Association | 1 | 1989 | 266 | 0.020 |
Why?
| | Congresses as Topic | 1 | 1989 | 204 | 0.020 |
Why?
| | Lung | 1 | 2019 | 3672 | 0.020 |
Why?
| | Periodicals as Topic | 1 | 1989 | 183 | 0.020 |
Why?
| | Population Surveillance | 1 | 2009 | 395 | 0.020 |
Why?
| | Immunity, Innate | 1 | 2011 | 731 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2009 | 1086 | 0.020 |
Why?
| | Lung Neoplasms | 1 | 2016 | 2207 | 0.010 |
Why?
| | Forecasting | 1 | 2004 | 333 | 0.010 |
Why?
| | Animals | 1 | 2024 | 32102 | 0.010 |
Why?
| | Drug Therapy, Combination | 1 | 2004 | 962 | 0.010 |
Why?
|
|
Caplan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|